Fundraising Fox
/Companies
Sign in

Knopp Biosciences

Pittsburgh, US · Founded 2010 · 2 known investors

Find your way into Knopp Biosciences

Sign up to see every warm intro you have to Knopp Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Knopp Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.

BiotechHealthtech

Founders & leadership

Knopp Biosciences was founded in 2010 by Thomas V. Petzinger, Jr. and Michael E. Bozik.

TVThomas V. Petzinger, Jr.
Thomas V. Petzinger, Jr.LLC Manager
MEMichael E. Bozik
Michael E. BozikLLC Manager
SD
Steven DworetzkyExecutive

Board

BA
Benjamin A. GomezLLC Manager
JSJeffrey S. McCormick
Jeffrey S. McCormickDirectorManaging Partner at Saturn Partners
GT
Gregory T. HebrankLLC Manager

Investors · 2

Solas BioVentureslisted by Solas BioVenturesChattanooga

How we know: Solas BioVentures's portfolio page · a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$61.9M disclosed across 6 rounds · 2012–2020

▶$1raisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KrestonExecutive Officer
  • C. David AdairDirector
  • James MatherExecutive Officer
  • Calman PrussinExecutive Officer
  • Steven DworetzkyExecutive Officer
  • Stephen E ButtsDirector
  • Jeffrey S. McCormickDirector
  • Thomas V. Petzinger Jr.Executive Officer, Director, Promoter
  • Gregory T. HebrankExecutive Officer, Director, Promoter
  • Michael E. BozikExecutive Officer, Director, Promoter
  • Benjamin A. GomezDirector
Offering amount
$1
Amount sold
$1
First sale
Dec 2020
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedOct 2020 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin A. GomezDirector
  • James MatherExecutive Officer
  • Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
  • Gregory T. HebrankExecutive Officer, Director, Promoter
  • C. David AdairDirector
  • Stephen E ButtsDirector
  • Jeffrey S. McCormickDirector
  • Mark KrestonExecutive Officer
  • Calman PrussinExecutive Officer
  • Steven DworetzkyExecutive Officer
  • Michael E. BozikExecutive Officer, Director, Promoter
Offering amount
$26M
Amount sold
$12.6M
Sales commissions
$472.9K
Proceeds to insiders
$2.6M
Placement agents
Saturn Capital, Inc.
First sale
Jun 2020
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.9MraisedJun 2020 · 78 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin A. GomezDirector
  • Calman PrussinExecutive Officer
  • James MatherExecutive Officer
  • Mark KrestonExecutive Officer
  • Thomas V. Petzinger, Jr.Director, Promoter
  • Jeffrey S. McCormickDirector
  • Gregory T. HebrankExecutive Officer, Director, Promoter
  • Michael E. BozikExecutive Officer, Director, Promoter
  • Steven DworetzkyExecutive Officer
Offering amount
$30M
Amount sold
$14.9M
Proceeds to insiders
$2.5M
First sale
Jul 2012
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KrestonExecutive Officer
  • James MatherExecutive Officer
  • Calman PrussinExecutive Officer
  • Steve DworetzkyExecutive Officer
  • Benjamin A. GomezDirector
  • Jeffrey S. McCormickDirector
  • Thomas V. Petzinger, Jr.Director, Promoter
  • Gregory T. HebrankExecutive Officer, Director, Promoter
  • Michael E. BozikExecutive Officer, Director, Promoter
Offering amount
$3M
Amount sold
$1M
Proceeds to insiders
$520K
First sale
Mar 2020
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.4MraisedApr 2015 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin A. GomezDirector
  • Jeffrey S. McCormickDirector
  • Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
  • Gregory T. HebrankExecutive Officer, Director, Promoter
  • Michael E. BozikExecutive Officer, Director, Promoter
  • Steven DworetzkyExecutive Officer
Offering amount
$12.8M
Amount sold
$5.4M
Sales commissions
$365.2K
Proceeds to insiders
$916K
Placement agents
Stillpoint Capital, LLC, MIP Global, Inc.
First sale
May 2014
Incorporated
Limited Liability Company, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Knopp Biosciences do?
Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
Who founded Knopp Biosciences?
Knopp Biosciences was founded by Thomas V. Petzinger, Jr., Michael E. Bozik in 2010.
Who are Knopp Biosciences's investors?
Knopp Biosciences's investors include Saturn Partners, Solas BioVentures.
How much funding has Knopp Biosciences raised?
Knopp Biosciences has disclosed $61.9M raised across 6 rounds.
Where is Knopp Biosciences headquartered?
Knopp Biosciences is headquartered in Pittsburgh, US.